Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A (GLA) in a squalene-based 2% stable emulsion (GLA-SE). In this randomized, double-blind study, 261 subjects aged ≥60 years received inactivated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Falloon, Judith, Talbot, H. Keipp, Curtis, Craig, Ervin, John, Krieger, Diane, Dubovsky, Filip, Takas, Therese, Yu, Jing, Yu, Li, Lambert, Stacie L., Villafana, Tonya, Esser, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585697/
https://www.ncbi.nlm.nih.gov/pubmed/28679495
http://dx.doi.org/10.1128/CVI.00157-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585697/
https://www.ncbi.nlm.nih.gov/pubmed/28679495
http://dx.doi.org/10.1128/CVI.00157-17

Ejemplares similares